Conyers advised Jazz Investments I Limited, a Bermuda company and a wholly-owned subsidiary of Jazz Pharmaceuticals plc, on the listing on the Bermuda Stock Exchange of US$575,000,000 1.875% Exchangeable Senior Notes due 2021 (the “Notes”) issued by Jazz Investments I Limited, which listing became effective on October 12, 2017, immediately after the de-listing of the Notes from the Global Exchange Market of the Irish Stock Exchange.
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs.
David J. Doyle, Kathleen Moniz and Kent Smith of Conyers’ Bermuda office worked on the matter working alongside A L Goodbody (London).